1. Scrip
  2. >>New Products

Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval

 
• By Jessica Merrill

Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.

(Shutterstock)
Key Takeaways
  • Alnylam’s Amvuttra secured an important approval for the treatment of ATTR with cardiomyopathy (ATTR-CM), a second and larger indication for the drug.
  • Chief commercial officer Tolga Tanguler told Scrip in an interview that the firm is off to a running start with the launch.
  • Amvuttra will compete against Pfizer’s Vyndaqel/Vyndamax and Bridge Bio’s Attruby, but carries a higher price.

Alnylam Pharmaceuticals’ Amvuttra (vitrisiran) will tap a substantially larger commercial opportunity with its US Food and Drug Administration approval for the treatment of ATTR with cardiomyopathy, but the company will need to establish a position for Amvuttra in a competitive

The company announced the FDA approval of a supplemental new drug application for Amvuttra on 20 March for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Rare Diseases

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal

 
• By Sushmita Panda

After dropping its lead program in December, Spruce has been exploring strategic options – and thinks it has a de-risked path for MPS IIIB therapy tralesinidase from BioMarin.

Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

 
• By Mandy Jackson

Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.